Table 3. Elevation of urinary Bcl-2 from healthy women and from patients with benign lesions, early (EOC) and late (LOC) stage ovarian cancer.

	ROC-AUC	95%	Tukey mean difference	95% CI
USF
Normal vs. benign	83%	15.8%	0.3586	0.4568	1.17*
Normal vs. all cancer	100%	100%	2.9193	2.2938	3.55*
Normal vs. EOC	100%	100%	2.0829	0.4936	3.67*
Normal vs. LOC	100%	100%	3.0308	2.1838	3.88*
Benign vs. all cancer	ND	ND	2.5607	2.0419	3.08*
Benign vs. EOC	ND	ND	1.7243	0.2037	3.24*
Benign vs. LOC	ND	ND	2.6722	1.9624	3.38*
EOC vs. LOC	ND	ND	0.9478	-0.58898	2.48
MDA
Normal vs. benign	71%	17.9%	0.5425	0.1608	0.92*
Normal vs. all cancer	90%	50.4%	1.5219	1.1686	1.87*
Normal vs. EOC	90%	44.4%	1.1355	0.2316	2.04*
Normal vs. LOC	90%	50.9%	1.5513	1.1592	1.94*
Benign vs. all cancer	ND	ND	0.9794	0.6944	1.26*
Benign vs. EOC	ND	ND	0.593	-0.2815	1.47
Benign vs. LOC	ND	ND	1.0088	0.6904	1.33*
EOC vs. LOC	ND	ND	0.4158	-0.4632	1.29
USF + MDA
Normal vs. benign	71%	17.39	0.5061	0.0834	0.93*
Normal vs. all cancer	93%	76.67%	1.8512	1.5286	2.17*
Normal vs. EOC	92%	66.23%	1.4172	0.4714	2.36*
Normal vs. LOC	93%	77.37%	1.8897	1.4545	2.32*
Benign vs. all cancer	ND	ND	1.3451	1.0831	1.61*
Benign vs. EOC	ND	ND	0.9111	-0.001	1.82
Benign vs. LOC	ND	ND	1.3837	1.0275	1.74*
EOC vs. LOC	ND	ND	0.4725	-0.4455	1.39

^*p < 0.01

ND, not determined